

File 126
81
82
83
The process of claim 75, wherein the nucleic acid sequence comprises the nucleotide sequence of SEQ ID NO:7, including the guanine nucleotide at position 389 of SEQ ID NO:7.

83. The process of claim 75, wherein recombinant opioid receptor polypeptide is chimeric.--

add E!
REMARKS

The specification has been amended to recite the priority data, to cancel claims 1-43 and 48-64 of the prior application, and to add new claims 65-83. Support for the new claims can be found in the Specification at least at pages 17, lines 12-24; page 32, lines 1-30; page 42, line 6- page 44, line 9; page 71, line 4 to page 73, line 10; page 76, lines 12-18; 121 , lines 20-25; and, in the originally filed claims. Applicant contends that no new matter has been added.

The filing fee has been calculated after amendment of the claims by the preliminary amendment. Should any additional fees under 37 C.F.R. §§ 1.16 to 1.21 be required, the Assistant Commissioner is hereby authorized to deduct said fees from Fulbright & Jaworski Deposit Account No. 50-1212/10020907/MBW.

Respectfully submitted,



Gina N. Shishima
Reg. No. 45,104
Attorney for Applicant

FULBRIGHT & JAWORSKI L.L.P.
600 Congress Avenue, Suite 2400
Austin, Texas 78701
512.418.3000

Date: July 27, 2000